BPC 157 Explained: Benefits, Safety & Oral vs Injectable Options When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling